Twist debuts cfDNA library preparation kit for liquid biopsy applications

Twist Bioscience Corporation launched the cfDNA Library Preparation Kit to enable liquid biopsy research. Liquid biopsies have gained prominence in critical applications such as cancer screening, including multi-cancer early detection screening and monitoring for minimal residual disease. Liquid biopsy tests are designed to accurately identify tumor variants within circulating tumor DNA ctDNA , which are often difficult to detect due to degraded or limited DNA presence. The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests. “Liquid biopsies can be life changing for patients, enabling earlier detection of cancer and profiling each patient’s unique tumor to inform personalized treatment plans,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Even with advancements in the sensitivity of tests that have enabled the liquid biopsy field to expand, some tumor variants remain incredibly difficult for researchers to detect in the earlier stages of disease. With exceptional accuracy and sensitivity enabled by high conversion rates, the Twist cfDNA Library Preparation Kit can help push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions.”